Graphical Abstract

Highlights:

Co-activation of receptor tyrosine kinases and non-receptor tyrosine kinases is a common feature in cancer. Cross-talk between different signaling pathways is the basis for poly-therapy in several tumors. Rewiring of cell signals occurs as a response to therapy.
PROGRAM

08:30: Welcome

8:45 - 9:00: Depression and cancer. Tracing BDNF signaling in plasma
- Rafael Rosell, Molecular and Cellular Oncology Laboratory, IGTP, Badalona, Spain

SESSION I
Chairpersons: Laura Bonanno, Jordi Codony

9:00 - 9:15: Mucinous lung adenocarcinoma
- Masaoki Ito, Dept of Surgical Oncology, Research Institute for Radiation Biology & Medicine, Hiroshima Univ, Japan; Pangaea Oncology, Barcelona

9:15 - 9:30: Molecular subtypes of SCLC
- Niki Karachaliou, Global Clinical Development, Merck, Darmstadt, Germany

9:30 - 9:45: EGF cancer vaccine antibodies in EGFR-wt patients(Phase III clinical trial BV-NSCLC -002)
- Jordi Codony, Pangaea Oncology, Barcelona

9:45 - 10:00: Anti-EGFR Vaccine Antibodies and Kinase Inhibitors in lung and colon cancer cells harboring KRAS, BRAF and PIK3CA mutations
- Silvia Garcia Roman, Pangaea Oncology, Barcelona

10:00 - 10:15: PD-L1 glycosylation
- Imane Chaib, Molecular and Cellular Oncology Laboratory, IGTP, Badalona

10:15 - 10:30: Triple MET/SRC/PIM inhibition in MET addicted tumors
- Laura Bonanno, Istituto Oncologico Veneto, Padova

SESSION II

10:30 - 10:50: Fishing for Cures: The Zebrafish as a Powerful Tool to Identify Novel Therapies against Glioblastoma by targeting MTH1 and beyond
- Linda Pudelko, PhD LMN Bio-Med Connecting Team, Merck KGaA, Darmstadt, Germany

10:50 - 11:10: What we have done with EGFR mutations in NSCLC in the last 10 years
- Niki Karachaliou, Global Clinical Development, Merck, Darmstadt, Germany

11:10 - 11:30: NGS and nCounter for precision medicine
- Miguel Angel Molina, Pangaea Oncology, Barcelona
SESSION III  
Chairperson: Niki Karachaliou

11:45 ÷ 12:05: Targeting macrophage polarization as a therapeutic approach in cancer  
- Maria Rosa Sarrias, Innate Immunity group, IGTP, Badalona

12:05- 12:20: Phase II trial of Durvalumab in HIV infected cancer patients that are ART-stabilized  
- Maria Gonzalez Cao, IOR, Quiron-Dexeus Hospital, Barcelona

12:20 ÷ 12:35: Differential gene expression in HIV infected cancer patients, ART-stabilized  
- Jill Bracht, ELBA ESR; Pangaea Oncology, Barcelona

12:35 ÷ 12:50: Characterization of human Peter Pan in cell cycle and apoptosis  
- Marina Keil, PhD LMN Bio-Med Connecting Team, Merck KGaA, Darmstadt, Germany

- Montserrat Sanchez-Cespedes, Institut de Recerca contra la Leucèmia Josep Carreras

13:10 ÷ 13:30: Lung cancer microbiome  
- Martyna Filipska, ELBA ESR, Molecular and Cellular Oncology Laboratory, IGTP, Badalona
- Roxana Chirinos, Hospital Universitari General de Catalunya, QuironSalud, Sant Cugat, Barcelona

13:30 ÷ 14:00: BREAK
SESSION IV
Chairpersons: Niki Karachaliou, Masaoki Ito

14:15 – 14:30: Immunotherapy trials
- Santiago Viteri, IOR, Quiron-Dexeus Hospital, Barcelona

14:30 – 14:45: ADRB2-BDNF tracking in cancer patients (DeCa trial)
- TBD, IOR, Quiron-Sagrat Cor Hospital, Barcelona

14:45 – 15:15: Driver EGFR, BRAF and KRAS mutations and co-alterations
- Jill Bracht, ELBA ESR; Pangaea Oncology, Barcelona

15:30 – 15:45: KRAS mutations and treatment
- Jill Bracht, ELBA ESR; Pangaea Oncology, Barcelona
- Masaoki Ito, Dept of Surgical Oncology, Research Institute for Radiation Biology & Medicine, Hiroshima Univ, Japan; Pangaea Oncology, Barcelona

15:45 – 16:00: The future of immunotherapy
- Niki Karachaliou, Global Clinical Development, Merck, Darmstadt, Germany

SESSION V
Chairpersons: Miguel Angel Molina, Imane Chaib

16:10 – 16:30: Circular RNA
- Carlos Pedraz Valdunciel, ELBA ESR, Molecular and Cellular Oncology Laboratory, IGTP, Badalona

16:30 – 17:00: PD-L1 in myeloid derived suppressor cells
- Jordi Petriz, Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias i Pujol, Badalona, Barcelona

17:00: CLOSING REMARKS
For **FREE REGISTRATION** and more general information, here is the meeting web:


**Molecular and Cellular Oncology Laboratory**

**Laboratory  P2- 07**
Cancer Biology and Precision Medicine

PI Rafael Rosell
P2- 08

**WITH SUPPORT FROM**

**Lilly**

**How to get to the Fundació Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol**

**By car / taxi:**
We are 20 minutes from the center of the city and the most convenient way to arrive is by car or taxi. We are close to the Hospital which can serve as a good point of reference:

Hospital Universitari Germans Trias I Pujol (Popularly known as Can Rutí). GPS: 41°29'06.66"N 2°14'21.27"E

From Barcelona take B20 (Rondas and Nus de la Trinitat) in direction Mataró. The hospital is well signed from the exit 21 (Badalona Centre) of the B20.

**With the collaboration of Lourdes Franquet and Stephanie Davis**